Sanofi and Armora Biosciences Develop Acne Vaccines

Acne treatments may be on the verge of a significant breakthrough as two companies develop vaccines to combat the skin condition.

Pimples are a common problem for many teenagers and can persist into adulthood, causing anguish and emotional distress. The development of vaccines targeting acne-causing bacteria could provide relief to those suffering from the condition. This new approach aims to tackle the root cause of acne by modulating the immune system's response to proteins released by skin bacteria.

The underlying theory is that the body overreacts to these proteins, triggering an immune response that leads to inflammation and acne. By inducing the production of antibodies against specific bacterial proteins, researchers hope to prevent or reduce acne. Two companies are working on this innovative approach: Sanofi is preparing for clinical trials in North America with an mRNA vaccine targeting at least one protein, while Armora Biosciences is focusing on a different protein.

Pharmaceutical giant Sanofi and US start-up Armora Biosciences are racing to develop vaccines that target specific bacterial proteins. According to Tomasz Zastawny at Armora, acne has a significant emotional impact on those affected, highlighting the need for better treatments. The link between acne and Cutibacterium acnes bacteria has been established for decades, with these bacteria thriving in hair follicles where oxygen levels are low.

C. acnes is a ubiquitous skin bacterium found on most people, regardless of whether they have acne or not. Its presence alone does not explain why some individuals develop acne while others do not. One contributing factor may be the surge in hormone levels during puberty, which can lead to an increase in fatty substances in the skin and affect bacterial growth.

The relationship between C. acnes and acne is complex, with experts pointing out that it's not just a straightforward infection. According to Richard Gallo at the University of California, San Diego, "Acne is very complicated." He notes that while C. acnes is present on most people, its presence alone does not usually cause problems.

However, in some cases, C. acnes can trigger a strong immune response within skin follicles, leading to a process called reactive adipogenesis. This involves cells in the skin turning into fat cells and releasing alarm signals and antimicrobial substances. Gallo describes this as "an inappropriate response," suggesting that it's not a normal way for the body to fight an infection.

Gallo's team has been investigating what triggers this immune response, and they believe that C. acnes may produce a toxin called Christie-Atkins-Munch-Petersen factor, or CAMP, in certain circumstances. The researchers have tried vaccinating mice against CAMP, with the aim of making the animals produce antibodies that neutralise the toxin.

Researchers are optimistic about the potential for mRNA vaccines to revolutionize acne treatments, according to studies conducted by Gallo's team.

Sanofi has developed an mRNA vaccine targeting CAMP and possibly other C. acnes proteins, although the company declined to discuss its exact contents with reporters.

The Sanofi trial is expected to begin soon, but it remains labeled as "not yet recruiting on the latest update from 18 September, indicating that results may take time to emerge.

Volunteers in the initial trials are likely to notice a difference in their acne within weeks, a departure from the typical months or years required for vaccine efficacy to be determined.

The connection between hyaluronic acid and acne has long been established, but researchers have discovered that certain bacteria, including those responsible for acne, produce an enzyme called hyaluronidase.

This enzyme is often associated with other applications, such as dissolving cosmetic fillers made from hyaluronic acid. However, some bacteria, like strep B, also produce hyaluronidase to facilitate their invasion of tissues.

Further investigation revealed that there are two main types of hyaluronidase: one breaks down hyaluronic acid into simple sugars, while the other produces large chunks that trigger an immune response.

Researchers found that the simple sugars type is more common among bacteria, but the large chunks" type is limited to free-living bacteria that don't need to evade immune systems.

Research on acne-causing bacteria has led to some intriguing findings that could revolutionize treatment options. Mouse studies conducted by a team revealed that certain strains of C. acnes, which cause acne-related inflammation, can be divided into two categories: those with large chunks and those with simple sugars.

While the simple-sugars type seems more common among bacteria, its impact on inflammation is relatively minimal. In contrast, the large-chunks strain causes significant inflammation, leading researchers to believe that targeting this specific form could lead to effective treatments.

A vaccine designed to stimulate antibodies against the large-chunks form of hyaluronidase enzyme has shown promise in mouse studies, reducing acne severity as effectively as inhibiting the enzyme with a small protein.

The reasons behind C. acnes' ability to trigger an immune response are still unclear, but one possibility is that it allows the bacteria to eliminate competitors and thrive in their environment. This theory could explain why some people experience more severe acne lesions.

It's also possible that antibiotics, commonly prescribed for acne, fail to provide long-term relief because they target all C. acnes strains, including those with beneficial properties. This highlights the limitations of current treatments, which often come with unwanted side effects, such as isotretinoin (Roaccutane), a more effective option but one associated with severe birth defects and other health issues.

Researchers are developing two competing approaches for acne vaccines that target specific proteins secreted by bacteria, potentially offering a game-changing solution for those struggling with the condition.

These vaccines aim to alter the skin's microbiome and do not directly target bacteria, reducing concerns about resistance and lasting side effects. The simultaneous development of two distinct approaches could provide multiple options for individuals with acne, increasing the chances of finding an effective treatment.